Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androgel in Hypogonadal Men with Type 2 Diabetes
NCT00141492Phase 2Completed
- Sponsor
- Solvay
- Start
- Oct 2004
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Testosterone TEPI patch in type 2 diabetes mellitus (T2DM) and Hypogonadism (2 arms), sponsored by Solvay. Primary endpoint: Hemoglobin A1c at 24 weeks. Started Oct 2004; status: completed.
02
Drugs
Testosterone TEPI patch
03
Conditions
type 2 diabetes mellitus (T2DM)Hypogonadism
Beyond the preview
Go deeper on NCT00141492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141492.